23andMe
-
Ancestry answered the DNA questions 23andMe couldn’t
A really awesome thing about being black is that ancestry can be very unclear because of, you know, slavery. Enter DNA kits. Read More
-
23andMe confirms $250 million round led by Sequoia
Genetics testing company 23andMe has formally announced that Sequoia Capital is leading an investment round in the company. This confirms the news we broke last week. The press release says that the final amount was $250 million and that Sequoia’s Roelof Botha will be taking a board seat. Others participating in the round include new investors Euclidean Capital, Altimeter Capital and… Read More
-
23andMe’s second act sits squarely in drug research and development
The company first began making moves early in 2015, forging a partnership with Pfizer to conduct a bit of drug research using 23andMe’s genetic data. The pact was formed in the midst of orders from the Food and Drug Administration that 23andMe cease sales of its consumer health report product, which drove a major portion of both 23andMe’s revenue and brand awareness at the… Read More
-
Equity podcast: Roku is going public, 23andMe raises $200M and Juicero is dead
Hello and welcome back to Equity, TechCrunch’s venture capital-themed podcast. This week Matthew Lynley, Katie Roof, and myself — Alex! — sat down with Micah Rosenbloom, an investor with Founder Collective to sit down and chew over the week’s news. We managed to not talk about Uber this episode, which was a welcome respite from the last few months during which we… Read More
-
23andMe hits $1.5B pre-money valuation in latest huge funding round
Following up on the news of 23andMe’s huge upcoming financing round, TechCrunch has learned that the company is raising the new financing at a $1.5 billion pre-money valuation. This compares to a $1 billion valuation in its last private round. Dan Primack over at Axios reported the same thing this morning, but we’ve heard from our sources the number is indeed accurate. Read More
-
23andMe is raising about $200 million, led by Sequoia
23andMe, the Mountain View-based genetic testing and analysis company, is raising close to $200 million in a funding round led by Sequoia Capital, multiple sources tell us. Sources say that Fidelity is also looking to participate. We’re now hearing that this round is being done at a $1.5 billion pre-money valuation. This is about 50% higher than the roughly $1 billion valuation from the… Read More
-
TechCrunch Disrupt SF 2017 will feature some of tech’s wildest success stories
TechCrunch Disrupt SF 2017 is less than a month away at Pier 48 in San Francisco. This year’s lineup includes a stellar group of speakers, including Pinterest’s Ben Silbermann, Golden State Warriors superstar forward (and also investor) Kevin Durant, Forerunner Venture’s Kirsten Green and Udacity co-founder Sebastian Thrun. Read More
-
Color Genomics goes beyond cancer with a test for heart health
Cancer and heart disease are the two leading causes of death in the United States. So far, Color Genomics has been focused on testing for mutations leading to a higher risk of certain cancers. But, today the four-year-old company is introducing a new category of genetic testing for cardiovascular health. The new Color Hereditary High Cholesterol Test will tell you if you have a genetic… Read More
-
Modern Fertility is offering a comprehensive fertility test for women who hope to be moms someday
There are a number of ways to find out more about your fertility these days — including from several at-home fertility test startups that have started to pop up in the last few years. Modern Fertility hopes to soon operate in much the same way, but with a more affordable option for testing 10 key hormones affecting women’s fertility. Read More
-
23andMe’s Anne Wojcicki is speaking at Disrupt SF
Discovering your heritage is just a spit-tube away these days, thanks to the pioneering efforts 23andMe, the OG of at-home DNA tests. The decade-old company forged the path towards consumer access to genetic health risks and in doing so, created a path for a myriad of rivals like Ancestry and Color Genomics to enter the industry. We’re excited to have CEO and founder Anne Wojcicki join us… Read More
-
EverlyWell rolls out three new DNA-based products for food sensitivity, metabolism and breast milk
There’s a lot going on in commercial DNA testing these days beyond what eye color you have or where your mitochondria comes from, and at-home lab testing startup EverlyWell hopes to cash in. The startup launched three new products today, based on your DNA to help get it there, including a food sensitivity test, DNA factors for your metabolism and breast milk DHA. Read More
-
Doggie DNA startup Embark raises $4.5 million in seed to find your puppy’s breed
Ever wanted to know the genetic mix of your mutt? Embark, a doggie DNA startup has raised $4.5 million in seed to expand its offering of genetic kits for your pup’s pedigree. Embark launched in Austin two years ago with its “Embark Dog DNA Test Kit” that tells dog owners their pet’s pedigree, where in the world their dog comes from and if they have a genetic variant for… Read More
-
9 promising at-home lab test startups for everything from fertility to STDs
It’s easier than ever to skip the doctor and go straight for the at-home test these days, thanks to updated regulations and the technology to match — and for many, it’s the answer to invasive and expensive hospital visits. A new army of startups has popped up in the last couple of years to offer you low-cost options for everything from breast cancer inheritance to HIV. Read More
-
Crunch Report | Jeff Bezos Sells $1B in Amazon Stock Annually to Fund Blue Origin
The Kriesel high-performance electric converted Porsche, Jeff Bezos sells $1 billion in stock annually to fund Blue Origin, Hyperloop One completes Vegas test track and 23andMe can now let you know if you have the genes for Parkinson’s. All this on Crunch Report. Read More
-
23andMe is finally allowed to tell you if you have the genes for Parkinson’s
The Food and Drug Administration finally gave 23andMe a long sought-after green light today to sell to consumers genetic tests and their accompanying health risk reports for up to 10 diseases, including late-onset Alzheimer’s and Parkinson’s. Read More
-
Crunch Network
Advances in AI and ML are reshaping healthcare
The application of AI/ML in healthcare is reshaping the industry and making what was once impossible into a tangible reality. Read More
-
23andMe reportedly no longer working on next-gen sequencing
23andMe won’t continue with next-generation DNA sequencing and has reportedly laid off the lab working on the project. About half-a-dozen workers were laid off from the Salt Lake City, Utah-based lab, according to BuzzFeed, which first reported the news. By our own count based on LinkedIn, at least five members of the lab have been let go, including its chief medical officer, Dr. Read More
-
Color Genomics raises $45 million to provide cheaper genetic tests that detect cancer risk
Othman Laraki and Elad Gil were sitting on Twitter’s roof deck after their previous company Mixer Labs had been acquired. Gil had brought a small hard drive with him — which happened to contain data on his genome being sequenced — and Laraki wanted to take a look at the data. That led to the original hypothesis of Color Genomics: what if you could apply the same principles… Read More
-
23andMe’s Anne Wojcicki has a plan to include better genetic data from people of color
One of the first consumer genetic testing companies, 23andMe says it aims to be at the forefront in gathering genetically diverse data throughout the world. The company just launched a standalone $99 ancestry service today as a way to offer those interested in their genetic lineage the ability to trace ancestors and relatives just by spitting into a tube. Ancestral DNA is something founder… Read More
-
Crunch Network
Innovation in genomics and the future of medtech
The field of medicine is in the process of being profoundly transformed by new technologies; much of this transformation comes from exciting advances in genomics. Although genomics is relatively unknown to the general public, innovations in the field have started to make headlines: Genetic testing startup 23andMe, the “gene editing” technology CRISPR and the ambitious 100,000… Read More
Message Us